Evidence map›Paper›PMID 35378764›Full record

ArticlebioRxiv : the preprint server for biology2022

An engineered ACE2 decoy receptor can be administered by inhalation and potently targets the BA.1 and BA.2 omicron variants of SARS-CoV-2.

Lianghui Zhang, Krishna K Narayanan, Laura Cooper, Kui K Chan, Christine A Devlin, Aaron Aguhob, Kristie Shirley, Lijun Rong, Jalees Rehman, Asrar B Malik and 1 more

Open access · greenAbstract readPreprint
PubMed Full text at PMC Publisher
In one paragraph

Article in bioRxiv : the preprint server for biology, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed, 22 citations in OpenAlex.

  1. Review
4 · The record

Corrections and comments

5 · Who and what money

Authors and funding

11 authors at 3 institutions in 1 country.

Lianghui ZhangDepartment of Pharmacology and Regenerative Medicine and the Center for Lung and Vascular Biology, The University of Illinois College of Medicine, Chicago, IL 60612, USA.
Krishna K NarayananDepartment of Biochemistry, University of Illinois, Urbana, IL 61801, USA.
Laura CooperDepartment of Microbiology and Immunology, The University of Illinois College of Medicine, Chicago, IL 60612, USA.
Kui K ChanCyrus Biotechnology, Inc., Seattle, WA 98101, USA.
Christine A DevlinDepartment of Biochemistry, University of Illinois, Urbana, IL 61801, USA.
Aaron AguhobCyrus Biotechnology, Inc., Seattle, WA 98101, USA.
Kristie ShirleyCyrus Biotechnology, Inc., Seattle, WA 98101, USA.
Lijun RongDepartment of Microbiology and Immunology, The University of Illinois College of Medicine, Chicago, IL 60612, USA.
Jalees RehmanDepartment of Pharmacology and Regenerative Medicine and the Center for Lung and Vascular Biology, The University of Illinois College of Medicine, Chicago, IL 60612, USA.
Asrar B MalikDepartment of Pharmacology and Regenerative Medicine and the Center for Lung and Vascular Biology, The University of Illinois College of Medicine, Chicago, IL 60612, USA.
Erik ProckoDepartment of Biochemistry, University of Illinois, Urbana, IL 61801, USA.
University of Illinois Urbana-Champaign · USCyrus BiotechnologyIllinois College · US

Funding

Mechanisms and Treatment of SARS-CoV-2 induced Lung Endothelial InjuryR01HL162308 · NHLBI · UNIVERSITY OF ILLINOIS AT CHICAGO · PI REHMAN, JALEES, RICHNER, JUSTIN · 2022 to 2025
$2.9M
Endothelial antigen presentation to T cells as a pathogenic mechanism in influenza-induced acute lung injury.R01HL157489 · NHLBI · UNIVERSITY OF PITTSBURGH AT PITTSBURGH · PI ZHANG, LIANGHUI · 2021 to 2025
$2.0M
Optimization of a broad and potent decoy receptor for SARS-associated virusesR43AI162329 · NIAID · ORTHOGONAL BIOLOGICS, INC. · PI CHAN, KUI KIU · 2021 to 2021
$257k
NHLBI NIH HHS R01 HL157489NHLBI NIH HHS R01 HL162308NIAID NIH HHS R43 AI162329
6 · The paper itself

Abstract

Monoclonal antibodies targeting the SARS-CoV-2 spike (S) glycoprotein neutralize infection and are efficacious for the treatment of mild-to-moderate COVID-19. However, SARS-CoV-2 variants have emerged that partially or fully escape monoclonal antibodies in clinical use. Notably, the BA.2 sublineage of B.1.1.529/omicron escapes nearly all monoclonal antibodies currently authorized for therapeutic treatment of COVID-19. Decoy receptors, which are based on soluble forms of the host entry receptor ACE2, are an alternative strategy that broadly bind and block S from SARS-CoV-2 variants and related betacoronaviruses. The high-affinity and catalytically active decoy sACE2

Identifiers

PMID35378764
PMCPMC8978935
OpenAlexW4220981600

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.